April 24, 2019
Advance Online
Advance Online
FDA Approves Skyrizi for Plaque Psoriasis
The latest interleukin-23 inhibitor is aimed at adults with moderate-to-severe psoriatic disease.
The latest interleukin-23 inhibitor is aimed at adults with moderate-to-severe psoriatic disease.
We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.